摘要
目的观察罗格列酮对糖耐量异常患者的治疗效果。方法比较119例糖耐量异常患者在饮食加运动控制的基础上口服罗格列酮和安慰剂干预治疗,经治疗1年后,检测空腹血糖(FPG)及葡萄糖耐量试验(OGTT)后2 h血糖(2hPG),总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白(HDL)、胰岛素抵抗指数、空腹胰岛素(FINS)和OGTT后2 h胰岛素(PINS)水平的变化。结果罗格列酮组和安慰剂组治疗前糖耐量比较差异无统计学意义(P>0.05)。罗格列酮组与安慰剂组相比FPG、2HPG、TC、TG、LDL、FINS、PINS及糖尿病发病率均明显下降,HDL-C升高。结论罗格列酮能够降低糖耐量异常(IGT)人群糖尿病的发病率,在调节血脂、减轻胰岛素抵抗的同时,可使糖耐量异常明显改善。
Objective To investigate the therapeutic efficacy of rosiglitazone on patients with impaired glucose tolerance. Methods 119 cases with impaired slucose tolerance were orally treated with rosiglitazone and placebo in addition to controlled diet plus exercise. The fasting plasma glucose （ FPG ）, postprandial plasma glucose （ 2hPG ）, triglyceride （ TG ）, cholesterol （ TC ）, low density lipoprotein （ LDL ）, high density lipoprotein （HDL） ,2 hours after oral glucose tolerance test （OGTT）, insulin （PINS） two hours after fasting insulin and OGTT,lipid, and insulin resistance levels in two groups were observed. Results There was no Significant difference of the glucose tolerance between placebo group and rosiglitazone group before therapy （P 〉 0.05 ）. The incidence of diabetes, FPG,2HPG, TC ,TG, LDL, FINS and PINS, and insulin resistance index were obviously decreased after treatment of rosiglitazone, while the HDL levels were increased as compared with placebo group （ P 〈 0.05 ）. Conclusion Application of rosiglitazone in the intervening treatment of impaired glucose tolerance subjects can reduce the incidence of diabetes and improve impaired glucose tolerance, while it can adjust lipid and degrade insulin resistance.
出处
《中国综合临床》
北大核心
2007年第10期902-904,共3页
Clinical Medicine of China
基金
湖南省中医药科研基金项目(2006-6301)
关键词
糖耐量异常
罗格列酮
干预
血脂
Impaired glucose tolerance
Rosiglitazone
Intervention
Lipid
